Manish Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manish Kumar has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Swiatecka-Urban
Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Va
2 shared publications - Hayrettin Yavuz
University of Virginia School of Medicine
2 shared publications - Himanshu Ballav Goswami
Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Lebanon, NH 03756, USA
2 shared publications - Martha L. Graber
Department of Surgery, Dartmouth Hitchcock Medical Center, and Geisel School of Medicine, Lebanon, NH, USA
2 shared publications - Sladjana Skopelja-Gardner
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Lebanon, NH
2 shared publications - Uta Erdbrügger
University of Virginia School of Medicine
2 shared publications
Latest Publications
- Open Access
- 7 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5585
Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- 7 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5585
Open AccessDiagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- Open Access
- 24 June 2025
- Published by MDPI AG in Preprints.org
Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a sig-nificant comorbidity that increasingly is linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary ex-tra-cellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease man-agement in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- 24 June 2025
- Published by MDPI AG in Preprints.org
Open AccessDiagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a sig-nificant comorbidity that increasingly is linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary ex-tra-cellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease man-agement in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.